A ligand-bound gold cluster for use in the treatment of adverse effects caused by an atypical antipsychotic in a subject, wherein the ligand-bound gold cluster comprises: a gold core; and a ligand bound to the gold core; wherein the atypical antipsychotic is olanzapine and/or clozapine; the adverse effects caused by the atypical antipsychotic are selected from the group consisting of obesity characterized by excessive body weight gain, lipid metabolism disorder, and glucose metabolism disorder; the ligand is one selected from the group consisting of L-cysteine and its derivatives, D-cysteine and its derivatives, cysteine-containing oligopeptides and their derivatives, and other thiol-containing compounds; the L-cysteine and its derivatives are selected from the group consisting of L-cysteine, N-isobutyryl-L-cysteine (L-NIBC), and N-acetyl-L-cysteine (L-NAC); the D-cysteine and its derivatives are selected from the group consisting of D-cysteine, N-isobutyryl-D-cysteine (D-NIBC), and N-acetyl-D-cysteine (D-NAC); the cysteine-containing oligopeptides and their derivatives are cysteine-containing dipeptides, cysteine-containing tripeptides or cysteine-containing tetrapeptides; the cysteine-containing dipeptides are selected from the group consisting of L -cysteine-L -arginine dipeptide, L -arginine-L -cysteine dipeptide, L -histidine-L -cysteine dipeptide, and L -cysteine-L -histidine dipeptide; the cysteine-containing tripeptides are selected from the group consisting of glycine-L -cysteine-L -arginine tripeptide, L -proline-L -cysteine-L -arginine tripeptide, L -lysine-L -cysteine-L -proline tripeptide, and L -glutathione; and the cysteine-containing tetrapeptides are selected from the group consisting of glycine-L -serine-L -cysteine-L -arginine tetrapeptide (GSCR), and glycine-L -cysteine-L -serine-L -arginine tetrapeptide (GCSR); and the other thiol-containing compounds are selected from the group consisting of 1-[ -2-methyl-3-thiol-1-oxopropyl]-L -proline, thioglycollic acid, mercaptoethanol, thiophenol, D-3-trolovol, N-(2-mercaptopropionyl)-glycine, dodecyl mercaptan, 2-aminoethanethiol, 3-mercaptopropionic acid, and 4-mercaptobenoic acid (p-MBA). a gold core; and a ligand bound to the gold core; wherein the atypical antipsychotic is olanzapine and/or clozapine; the adverse effects caused by the atypical antipsychotic are selected from the group consisting of obesity characterized by excessive body weight gain, lipid metabolism disorder, and glucose metabolism disorder; the ligand is one selected from the group consisting of L-cysteine and its derivatives, D-cysteine and its derivatives, cysteine-containing oligopeptides and their derivatives, and other thiol-containing compounds; the L-cysteine and its derivatives are selected from the group consisting of L-cysteine, N-isobutyryl-L-cysteine (L-NIBC), and N-acetyl-L-cysteine (L-NAC); the D-cysteine and its derivatives are selected from the group consisting of D-cysteine, N-isobutyryl-D-cysteine (D-NIBC), and N-acetyl-D-cysteine (D-NAC); the cysteine-containing oligopeptides and their derivatives are cysteine-containing dipeptides, cysteine-containing tripeptides or cysteine-containing tetrapeptides; the cysteine-containing dipeptides are selected from the group consisting of L -cysteine-L -arginine dipeptide, L -arginine-L -cysteine dipeptide, L -histidine-L -cysteine dipeptide, and L -cysteine-L -histidine dipeptide; the cysteine-containing tripeptides are selected from the group consisting of glycine-L -cysteine-L -arginine tripeptide, L -proline-L -cysteine-L -arginine tripeptide, L -lysine-L -cysteine-L -proline tripeptide, and L -glutathione; and the cysteine-containing tetrapeptides are selected from the group consisting of glycine-L -serine-L -cysteine-L -arginine tetrapeptide (GSCR), and glycine-L -cysteine-L -serine-L -arginine tetrapeptide (GCSR); and the other thiol-containing compounds are selected from the group consisting of 1-[ -2-methyl-3-thiol-1-oxopropyl]-L -proline, thioglycollic acid, mercaptoethanol, thiophenol, D-3-trolovol, N-(2-mercaptopropionyl)-glycine, dodecyl mercaptan, 2-aminoethanethiol, 3-mercaptopropionic acid, and 4-mercaptobenoic acid (p-MBA).